Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection

Table 4

Patients with vitamin D < 10 ng/mL at baseline. Objective PTH < 65 pg/mL.

	Univariate analysis			Multivariate analysis
	Objective yes; 56 (66.7)	OR (95% CI)		OR (95% CI)
VitD supplements
Yes	41 (66.1)	0.91 (0.32–2.85)	0.86	1.05 (0.34–3.24)	0.92
No	15 (68.2)
TDF exposure
Yes	20 (52.6)	3.24 (1.26–8.35)	0.01	3.77 (1.36–10.43)	0.01
No	36 (78.3)
NNRTI exposure
Yes	23 (67.3)	1.08 (0.43–2.72)	0.87	3.36 (0.55–20.50)	0.19
No	33 (66)
PIs exposure
Yes	28 (59.6)	2.11 (0.82–5.46)	0.12	7.04 (1.09–45.47)	0.04
No	28 (75.7)